Figure 2.

Combining A8301 Treatment with HSV1716 Oncolytic Virotherapy Enhances Anti-tumor Efficacy

(A) A schematic of the treatment regimen. Mice were give intratumoral vehicle control or 6 mg/kg A8301 every other day for 20 days. During the first week of treatment, these mice also received three intratumoral 1 × 10⁸ PFU doses of HSV1716 or an equivalent volume of PBS. (B) Average tumor volumes for each treatment group plotted until the first mouse reached endpoint criteria. (C) Kaplan-Meier survival curves demonstrating potency of combined therapy. A log rank test was used to determine statistical significance. n = 5 mice per group for M3-9-M studies; for 76-9 studies, n = 8 mice for vehicle and A8301 groups, and n = 7 for HSV1716 and combination therapy groups. *p < 0.05. Error bars represent SD.